Yelak Biru was diagnosed with multiple myeloma at 25 and given just a few years to live. Thirty years later, he's thriving.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and ...

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

Lives Lived: From the moment he signed with the Tokyo Yomiuri Giants, Shigeo Nagashima was baseball royalty. He led his team to nine consecutive championships in a decade-spanning postwar dynasty that ...

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously via an on-body injector in relapsed or refractory multiple myeloma support the potential use of ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...